11 result(s) for 'Tonsil'
1 - 10 of 11 results for 'Tonsil'
Sort by
Show
Antigen Backgroundp16 (INK4a) (Cyclin-dependent kinase inhibitor 2A (CDKN2A)) is a tumour suppressor protein associated with cell cycle progression, specifically in the regulation of transition from G1 phase of the cell cycle in to the S phase. Oncogenic mutations in the CDKN2A gene that encodes p16 (resulting in over or under expression of the protein) is associated with a wide range of cancers and cancer precursor lesions.Disclaimerp16 is recom...
Slide 1
Hello, hello; thank you so much for that introduction. Let's get started. Oh, I'm sorry, I just need to hit this next button here. So my name is Mark Lawson.
Thank you for joining us in this webinar. I'm here to present BOND RX tips, tricks, and optimization. It's going to be a user guide from the BOND RX and chromogenic multiplexing in the research application.
Slide 2
So, my name is Mark Lawson. I'm an application specialist on the Life Sciences team at Leica Biosystems I provide technical support for the Life Sciences portfolio, including but not limited to the BOND RX, the BOND RXm, and a wide array of reagents. So I've worked in the histology field for about 15 years and in both clinical and research spaces. I started off as a histotechnologist and worked my way up...
Phenotyping Tumor Microenvironment Using DNA Barcoded Multiplex Technology Chifei Sun GSK IVIVTBIBCellular Biomarkers Collegeville, PA
I have no conflict of interests with Leica Biosystems, Ultivue and Indica Labs. – All the materials used in this presentation are for educational purpose only. – The human biological samples were sourced ethically, and their research use was in accord with the terms of the informed consents under an IRB/EC approved protocol. Statement 9/25/2020 2
Understand the complexity of tumor microenvironment and its importance in drug development – Introduce the Ultivue DNA barcoding and exchange technology for multiplex immunofluorescence – Highlight the processes of image fusion, spatial analysis and colocalization of markers on individual cells Learning...
Get tips for better ISH staining in this guide. Each step provides a valuable reminder of good histology practice and also helps with troubleshooting when unacceptable results do occur.
Biomarkers
AE1/AE3 (1)
AMACR (2)
BCL6 (1)
CD163 (2)
CD20 (2)
CD3 (9)
CD4 (5)
CD68 (5)
CD8 (10)
CDX2 (2)
CK20 (5)
Ck5 (4)
...
Antecedentes de antigénioLAG-3 (Lymphocyte Activation gene 3, CD223) é uma proteína de transmembranas de aminoácido 503. Desempenha um papel na regulação negativa da proliferação celular e ativação de células T, de forma semelhante a CTLA-4 e PD-1. O LAG3 desempenha um papel no esgotamento de respostas de células T no cancro e, portanto, é objeto de extensa investigação em conjunto com outros marcadores imunomoduladores relacionados.Isenções de r...
Antecedentes de antigénio TIM-3 (T-cell Immunoglobulin and Mucin Domain-Containing 3, Hepatitis A Virus Cellular Receptor, HAVCR2). TIM-3 é uma transmembrana de Tipo I que pode ser expressa em tumores e células imunitárias. É expressa em múltiplas células imunitárias, incluindo células T auxiliares de tipo 1 (Th1), células T Th17 e CD8+, Linfócitos Infiltrantes de Tumor, células T reguladoras (Tregs) e células imunitárias inatas.Isenções de respo...
Antecedentes de antigénioFOXP3 (Forkhead Box Protein 3, Scurfin) é um membro da família de caixa forkhead (FOX) de fatores de transcrição. Estas proteínas são caracterizadas por um domínio de ligação do ADN de forkhead altamente conservado. A FOXP3 tem um papel importante na regulação imunitária, com o seu efeito na redução da expressão de Interleucina-2, causando uma função reduzida das células T auxiliares. O papel da FOXP3 no cancro é multifac...
Human papillomaviruses (HPVs) are the etiologic agents for a significant fraction of many cancers in humans. Our understanding of the pathogenesis of these tumors has led to almost continuous refinement in our approach to managing patients at risk for these...
Different types of cancers frequently metastase to bone tissue. Treatment planning decisions are often based upon histology and special staining of these distant sites of disease. These decisions may rely on the outcome of immunohistochemistry, in situ...